Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors usually driven by the mutational activation of receptor tyrosine kinases, KIT, or PDGFRA. Oncogenic activation of phosphatidylinositide-3-kinase (PI3K), a downstream effector in the KIT signaling pathway, has been identified in different types of cancer, with the PI3K 110α subunit encoded by PIK3CA being a common mutational target. In this study, the mutational hotspot in the PIK3CA kinase domain encoded by exon 20 was evaluated in 529 imatinib-naive GISTs using PCR amplification and Sanger sequencing. Eight mutations (two co-existing in one tumor) were identified. Subsequently, The cobas PIK3CA Mutation Test was employed to evaluate mutational hotspots in exons 1, 4, 7, and 9 in 119 PIK3CA exon 20-wild type tumors. In two cases, mutations in exons 1 and 9 were identified. In one GIST, previously undetected by Sanger sequencing, the exon 20 mutation was discovered. Altogether, eight primary and two metastatic GISTs carried PIK3CA mutations. The size of primary PIK3CA-mutant GISTs was ≥ 14 cm (mean size 17 cm), and mitotic activity varied from 0 to 72 per 50HPF (mean 5/50HPF). Follow-up data showed short survival in 6 of 7 studied cases. Detection of PIK3CA mutations in large or metastatic KIT-mutant GISTs may suggest that PIK3CA-mutant clones have a proliferative advantage during disease progression. Tyrosine kinase inhibitors have been successfully used in GIST treatment. However, resistance frequently develops due to secondary KIT mutations or activation of downstream to KIT signaling pathways, such as the PI3K/AKT/mTOR pathway. PIK3CA mutations similar to the ones detected in GISTs have been shown to cause such activation. Therefore, genotyping of PIK3CA in GISTs might help to pinpoint primary and metastatic tumors with the potential to develop resistance to tyrosine kinase inhibitors and guide therapy with PI3K inhibitors.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. In general, GISTs are driven by mutational, oncogenic activation of receptor tyrosine kinases, KIT, or platelet-derived growth factor receptor α (PDGFRA), although subsets of KIT/PDGFRA-wild-type tumors have been identified and include succinate dehydrogenase (SDH)-deficient GISTs, neurofibromatosis 1 (NF1)-associated GISTs, BRAF mutant GISTs, and the so-called 'quadruple wild-type tumors' that lack mutations in KIT, PDGFRA, BRAF, and SDH genes. 1,2 Phosphatidylinositol 3-kinase, catalytic, alpha (PIK3CA) encodes the p110α catalytic subunit of phosphatidylinositide-3-kinase (PI3K), a lipid kinase, downstream effector in the KIT signaling pathway that promotes cellular growth, proliferation, and survival. Activation of PI3K/AKT/mTOR signaling pathway has been reported in different types of human cancer, and is often caused by PIK3CA mutations. 3 PIK3CA mutations frequently coexist with mutational activation of other oncogenes, such as BRAF and RAS. 4 Because the presence of PIK3CA mutations might negate the effect of the KIT inhibitor and indicate tumor response to PI3K/AKT/mTOR axis inhibitors, the mutation status of PIK3CA could be a factor in the selection of targeted therapy. 5, 6 Recently, PIK3CA mutations have been reported in two primary gastric GISTs: one concurrent with a KIT mutation and another with the HRAS mutation, and in treatment-resistant metastasis of a BRAF-mutant GIST. [7] [8] [9] Thus, activation of the PI3K/AKT/mTOR signaling pathway may have a role in both pathogenesis and the progression of GISTs. The presence of the PIK3CA mutation could indicate an alternative treatment inhibiting the PI3K/AKT/ mTOR signaling pathway for patients with advanced and metastatic tumors, as opposed to KIT inhibitor therapy. The aim of this study was to determine the frequency of PIK3CA mutations in imatinib-naive GISTs and their role in GIST biology and pathogenesis.
Materials and methods

Study Material
The analyzed cohort of 529 GISTs contained primary tumors from different locations, including the esophagus (n = 7), stomach (n = 214), small intestine (n = 127), large intestine with rectum and anus (n = 32), and intra-abdominal (n = 141) and metastatic extra-abdominal GISTs (n = 4). The intra-abdominal category included tumors involving omentum, retroperitoneum, and GISTs largely disseminated in the abdominal cavity at the time of diagnosis. In all cases, GIST diagnosis was confirmed by positive KIT (CD117) and/or ANO1 (DOG1) immunohistochemistry. Among gastric GISTs, 16 SDH-deficient tumors were identified following SDHB and SDHA immunohistochemistry. In the majority of cases, CD34, SMA, and S100 immunohistochemistry and KIT, PDGFRA, BRAF, HRAS, and KRAS genotyping data were available. Tumor size was documented in 347 primary GISTs. There were 195 tumors o 10 cm and 152 tumors 410 cm. Furthermore, in 71 cases, intra-abdominal dissemination or extra-abdominal metastases were present at the diagnosis. (1) PIK3CA1F 5′-AGGAGATGTGTTACAAGGCT-3′ and PIK3CA1R 5′-TTGTGTGGAAGATCCAATCC-3′ and (2) PIK3CA2F 5′-TGCATACATTCGAAAGACC C-3′ and PIK3CA2R 5′-TTGTGTGGAAGATCCAATC C-3′. The PCR product sizes for these two assays were 243 and 128 bp, respectively. PCR amplification products were purified using the QIAquick Gel Extraction Kit (Qiagen, Valencia, CA, USA) following agarose gel electrophoresis and then sequenced directly with forward and reverse primers. Cases revealing sequence variations were evaluated at least twice to ensure reproducibility of the PCR amplification and sequencing results. In one case, PIK3CA exon 20 PCR amplification products were cloned into plasmid using the TOPO TA Cloning Kit (Invitrogen by Life Technologies) and subsequently sequenced. The sequences were analyzed following alignment with PIK3CA, NG_012113.2 and NM_006218.2:c reference sequences (www.ncbi.nml.nih.gov). Known PIK3CA mutant colon carcinomas were used as a positive controls. The Sanger sequencing service was performed by MacrogenUSA (Rockville, MD, USA).
Study Design
The cobas PIK3CA Mutation Test. The cobas PIK3CA Mutation Test (Roche Molecular Systems, Pleasanton, CA, USA), a real-time PCR assay, allows detection of mutations affecting the following codons: p.R88 in exon 1, p.N345 in exon 4, p.C420 in exon 7, p.E542, p.E545 and p.Q546 in exon 9, and p.M1043, p.H1047, and p.G1049 in exon 20. Genotyping using The cobas PIK3CA Mutation Test was performed following the protocol provided by the manufacturer. 
Results
Molecular Studies
Sanger sequencing. Sanger sequencing of the PCR amplified PIK3CA exon 20 revealed eight mutations in seven GISTs. Examples of Sanger sequencing are shown in Figure 1 . All mutations consisted of single-nucleotide substitutions: c.3103G4A, c.3127A4G, c.3137C4T, c.3139C4T, c.3140A4G, c.3140A4T, c.3143A4G, and c.3158C4T. At the protein level, these substitutions would lead to p. A1035T, p.M1043V, p.A1046V, p.H1047R, p.H1047L, p.H1047Y, p.H1048R, and p.T1053I mutations, respectively. In one tumor, two substitutions, c.3103G4A and c.3158C4T, were detected. The cloning and sequencing of PCR products confirmed the presence of these mutations on two different alleles. All mutations identified in this study were previously reported in other tumors (Catalog of somatic mutations in cancer, cancer.sanger.ac.uk/cosmic).
In three cases, initially identified substitutions (c.3117C4T, c.3152G4A, and c.3153G4A, the cause of p.F1039F and p.W1051* PIK3CA mutations) could not be confirmed by the sequencing of two independent PCR amplification products (Figure 2 ). Subsequently, two of these cases were evaluated by Ion Torrent next-generation sequencing, which did not confirm the presence of clones with c.3152G4A and c.3153G4A PIK3CA mutations. However, due to the poor DNA quality, the sequencing coverage of the analyzed regions was only 353 and 145 reads, respectively.
The cobas PIK3CA Mutation Test. Three additional PIK3CA mutants were identified in 120 GISTs evaluated using The cobas PIK3CA Mutation Test (Table 1) . These mutants involved p.R88 in exon 1, p.E545 in exon 9, and p.H1047 in exon 20. The latter mutant was not detected via Sanger sequencing, while the two former ones were not tested by that assay.
Clinicopathological Profile of PIK3CA Mutant GISTs
The clinicopathologic data of PIK3CA mutants are summarized in Table 2 . The 10 patients included 7 men and 3 women (mean age, 58 years). There were four gastric and one small intestinal primary GIST, one liver metastasis of a small bowel GIST, three retroperitoneal GISTs with small intestinal GIST-like morphology, and one GIST metastatic to the abdominal wall from an unknown primary tumor. The tumor size of all primary PIK3CA mutant GISTs was ≥ 14 cm (mean and median size, 17 cm), and mitotic activity varied from 0 to 72 per 50HPF (median, 5/50 HPFs).
Nine PIK3CA mutant GISTs showed spindle cell or spindle to ovoid cell morphology (Figure 3) . Epithelioid cell morphology was seen in the abdominal wall metastatic GIST with unknown primary tumor. All tumors were KIT and DOG1 positive, while CD34 and SMA were expressed in seven and one cases, respectively (Figure 4) . The follow-up available in the seven cases revealed death of the disease for two cases, with median survival time o9 months and overall short survival o35 months in four additional cases (in which the cause of death was not available). PIK3CA mutations were concurrent with KIT exon 11 mutations in all 9 analyzed cases. 
Frequency of PIK3CA Mutations in GIST
PIK3CA exon 20 mutations were identified by Sanger sequencing in 1.3% (7 of 529) of analyzed GISTs. However, if tumors o 10 cm were excluded, then the frequency rose up to 2.7% (6 of 223). In a similar cohort, the frequency of PIK3CA mutations other than those in the exon 20 PIK3CA hot-spot was 2.7% (2 of 75), as documented by The cobas PIK3CA Mutation Test. Also, this real-time PCR assay was more sensitive than Sanger sequencing and identified one additional exon 20 mutant previously undetected by the Sanger sequencing. Based on the above data, we estimated that PIK3CA mutations in large (410 cm) and advanced GISTs might reach a 5-6% frequency.
Discussion
Phosphatidiylinositol 3-Kinase, or PI3K, is a lipid kinase, a downstream effector in the KIT signaling pathway that is thought to promote processes, such as cellular growth, proliferation, and survival. Oncogenic activation of the PI3K pathway has been implicated in different types of cancer. Activation of the PI3K/AKT/mTOR pathway contributes to a more aggressive tumor phenotype, which results in shorter survival and poor treatment outcome. 10 Genetic or epigenetic mutations affecting PI3K, PI3K downstream kinases, such as AKT or mammalian target of rapamycin (mTOR), and PTEN, a major PI3K-negative regulator, have been reported. 3, 5, 6 Relatively little is known about the genetic alteration of PI3K/AKT/mTOR pathway in GISTs, although one study reported frequent mono-allelic loss of PTEN, a negative regulator of PI3K. 11, 12 In addition, activation of the PI3K/AKT pathway was proposed to be involved in tumor cell survival in imatinib-sensitive and -resistant GISTs. 13 PIK3CA, a gene that encodes the p110α catalytic subunit of PI3K, has been shown to be mutated in common carcinomas, malignant melanoma, and some sarcomas. The majority of PIK3CA mutations cluster in exon 9 and exon 20, encoding helical and kinase domains respectively, although activating mutations in other PIK3CA regions including exons 1, 4, and 7 have been reported. 3 In this study, a large cohort of imatinib-naive GISTs was screened for PIK3CA mutations and 10 mutants were identified. A great majority of these mutations were located in exon 20, with four of them affecting codon 1047. This codon was mutated in all three previously reported PIK3CA mutant GISTs. [7] [8] [9] Thus, similarly to other cancer, p.H1047 appears to be the most common mutational hotspot in GISTs. One tumor revealed two co-existing PIK3CA exon 20 mutations. The co-existence of two different PIK3CA mutations has been previously reported in breast cancer and linked to more aggressive clinical outcomes. 14, 15 A previous study based on immunohistochemistry suggested that activation of the mTOR signaling pathway is characteristic for the PDGFRA mutant and wild-type GISTs, rather than KIT mutant GISTs. 16 In our study, all nine analyzed PIK3CA mutants turned out to be KIT exon 11 mutants. Similarly, one of three previously reported PIK3CA mutant GISTs carried KIT K558_E562del, typical of GISTs. 7 One PIK3CA mutation was reported in KIT/PDGFRA-wild type, BRAF V600E mutant GIST metastasis during BRAF-inhibitor treatment, at the time of disease progression. 8 Primary GISTs driven by BRAF mutations are exceptionally rare. 7, 17 In the current study, PIK3CA was evaluated in one BRAF mutant GIST and revealed wild-type sequences.
Nevertheless, a p.H1047R PIK3CA mutation co-existing with a p.G12V HRAS mutation was identified by next-generation sequencing in a high-grade gastric tumor reported as 'quadruple wild type' GIST. 9 Thus, in rare cases, PIK3CA mutations might have a role in wild-type GIST pathogenesis. In our study, no tumors with co-existing PIK3CA and HRAS or KRAS mutations were identified by Sanger sequencing.
Previous studies documented p.G12R and p.G12V KRAS mutations, respectively, in an imatinib-resistant lesion of disseminated GIST and in an anaplastic KIT-negative tumor developed following long-term imatinib therapy for CML. 9, 18 Based on previous studies, the frequency of RAS mutations in imatinib-naive GISTs remains very low. 19 More recently, a KRAS G12V mutation at 29% allele frequency has been reported in an SDH-deficient highly malignant gastric GIST. 20 No PIK3CA, HRAS, and KRAS mutations were identified in 16 SDH-deficient GISTs analyzed in this study.
In this study, all GISTs harboring PIK3CA mutations were large (410 cm) tumors. Also, previously published PIK3CA mutants represented high-grade primary or metastatic GISTs. The presence of PIK3CA mutations in such tumors may PIK3CA mutations in GIST suggest that PIK3CA mutant clones have proliferative advantage and can become dominant in a late stage of the GIST genetic evolution. These mutations can also arise without the selection pressure of a KIT tyrosine kinase inhibitor, such as imatinib mesylate.
Imatinib mesylate, a KIT and PDGFRA tyrosine kinase inhibitor, has been used for the treatment of primary advanced and disseminated GISTs. However, both primary and secondary resistance acquired after or during initially successful treatment occurs. 21 The resistance could be related to the mutational activation of downstream pathways, such as the PI3K/AKT/mTOR pathway. Thus, identification of PIK3CA mutations in primary KIT mutant GIST may have significant clinical implications in the choice of a kinase inhibitor therapy, as the mutational activation of PI3K may nullify the effect of KIT inhibition due to independent downstream activation of the signaling pathways. Also, the type of PIK3CA mutation might influence the response to PI3K/AKT/mTOR inhibitors. 22 Applicability of Sanger sequencing in the analysis of PIK3CA mutations has limitations. The presence of the pseudogene on chromosome 22 with high (495%) homology to the PIK3CA exon 9 sequence hampers detection of mutations by Sanger sequencing. Thus, in this study, The cobas PIK3CA Mutation Test was employed to search for common PIK3CA exon 9 mutations. This real-time PCR assay, developed to detect changes in PIK3CA mutational hotspots, is more sensitive than Sanger sequencing. 23 In our study, the comparison of these two methods revealed a high concordance with only two variances. In one case, a rare mutation identified by Sanger sequencing was not detectable by The cobas PIK3CA Mutation Test and, in the second case, Sanger sequencing turned to be less sensitive in the detection of a mutant minority clone.
The reproducibility of Sanger sequencing results was generally good. However, in three cases, initially detected heterozygous G4A and C4T mutations were not seen in subsequent PCR amplifications. Although such results might be a consequence of intratumor heterogeneity, 24 the next-generation sequencing failed to detect subclones carrying these mutations. Because the C:G4T:A substitutions represent the most common sequencing artifacts detected in PCR of formalin-fixed paraffin-embedded DNA, 25 it is possible that early sequencing results from these two cases represented random PCR amplification artifacts. Studies of multiple, well-preserved DNA samples with next-generation ultra-deep sequencing could help to distinguish intratumor clonal heterogeneity from random PCR amplification artifacts. 26 In summary, we reported the rare occurrence of PIK3CA mutations in imatinib-naive GISTs. These mutations occurred predominantly in large and clinically aggressive GISTs, suggesting that the expansion of PIK3CA mutant clones is an additional oncogenic event that can also develop without selection pressure caused by a kinase inhibitor. Detection of these mutations is significant for the selection of targeted therapy as their presence may preclude the use of a tyrosine kinase inhibitor and instead require inhibitors for the PI3K/AKT/mTOR pathway.
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